<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433666</url>
  </required_header>
  <id_info>
    <org_study_id>METC11-3-035</org_study_id>
    <secondary_id>ZonMw (the Netherlands)</secondary_id>
    <secondary_id>2011-002070-23</secondary_id>
    <nct_id>NCT01433666</nct_id>
  </id_info>
  <brief_title>Roflumilast and Cognition</brief_title>
  <acronym>EEGrofl</acronym>
  <official_title>Effects of Roflumilast on Cognition in Healthy Adults: a Behaviour-EEG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current project is to validate PDE4 inhibitors as a target for cognition
      enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will
      demonstrate whether memory, but also attention, information processing or executive function
      improves with the PDE4 inhibitor roflumilast in healthy humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of words remembered on Verbal learning task</measure>
    <time_frame>1hr after drug intake</time_frame>
    <description>30 monosyllable words will be displayed on a computer screen. Immediately after the presentation and after 45 minutes, subjects will be asked to report as much words as they remember. In addition, a recognition trial is conducted. Here, 30 words will be presented; 15 new words and 15 from the original list. Subjects have to indicate whether the word is old or new.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>roflumilast 100ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>roflumilast 300ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>roflumilast1000ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roflumilast (EU: Daxas, USA: Daliresp)</intervention_name>
    <description>Acute intervention: 1 time each dose on different days. Capsulated</description>
    <arm_group_label>roflumilast 100ug</arm_group_label>
    <arm_group_label>roflumilast 300ug</arm_group_label>
    <arm_group_label>roflumilast1000ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute intervention: single administration, capsulated form.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roflumilast</intervention_name>
    <description>Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.</description>
    <arm_group_label>roflumilast 100ug</arm_group_label>
    <arm_group_label>roflumilast 300ug</arm_group_label>
    <arm_group_label>roflumilast1000ug</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Daxas</other_name>
    <other_name>Daliresp</other_name>
    <other_name>PDE4-inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 35 years of age

          -  Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity
             (corrected or uncorrected),

          -  Body mass index between 18.5 and 30

          -  Willingness to sign an informed consent.

          -  Positive evaluation on the memory screening

        Exclusion Criteria:

          -  History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal,
             haematological, or psychiatric illness

          -  First-degree relative with psychiatric disorder (in particular major depressive
             disorder and suicidality)

          -  Excessive drinking (&gt;20 glasses of alcohol containing beverages per week)

          -  Pregnancy or lactation

          -  Use of chronic medication other than oral contraceptives

          -  Use of recreational drugs in the 2 weeks preceding participation

          -  Smoking

          -  Orthostatic hypotension

          -  Lactose intolerance

          -  Sensory or motor deficits which could reasonably be expected to affect test
             performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos H. Prickaerts, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University, Faculty of Psychology and Neuroscience</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Marlies van Duinen</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

